# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Lake Street analyst Ben Klieve maintains Evogene (NASDAQ:EVGN) with a Buy and lowers the price target from $30 to $12.
Approximately 5,079,000 Ordinary Shares Outstanding Post-Split; Trading On Nasdaq Capital Market Begins July 25, 2024, And On T...
More than one dozen novel microbes identified for row crops suffering from extreme weather conditionsTEL AVIV and REHOVOT, Isra...
Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), is pleased to ann...
Casterra Ag Ltd., a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), is a provider of an integrated solution for industri...